ArticleDigestive diseases (Basel, Switzerland)2025
Combined [18F]-Fluorodeoxyglucose Positron Emission Tomography-MR Imaging: A Promising Tool for Diagnostics of Small Bowel Crohn's Disease.
Article in Digestive diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06796959 (Combined [18F]-FDG PET-MRI in Diagnostics and Surveillance of Small Bowel Crohn's Disease), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined [18F]-FDG PET-MRI in Diagnostics and Surveillance of Small Bowel Crohn's Disease (CD-PET)
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic utility of FDG and FAPI PET imaging in crohn's disease: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Combined [European journal of nuclear medicine and molecular imaging · 2026Observational
- Clinical Characteristics of Crohn's Disease-Associated Cancer with a Focus on Endoscopic Surveillance.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiagnostics of small bowel Crohn's disease (CD) can be difficult. Combined positron emission tomography-magnetic resonance enterography (PET-MRE) can be used to evaluate intestinal metabolism, but clinical use has been limited due to accessibility, costs, absence of standardized methods, and diagnostic thresholds. Our aim was to show that combined PET-MRE can be used to diagnose active small bowel CD.
methodsWe performed a fusion PET-MRE scan with [18F]-FDG tracer to 30 patients with suspected small bowel CD in colonoscopy. Standardized uptake values (SUVs) were measured from small bowel. The diagnosis was confirmed with small bowel capsule endoscopy. Clinicians chose appropriate medication to each patient blinded from SUV results. Endoscopic, laboratory, and MRE findings were investigated in relation to SUV.
resultsFusion PET-MRE outperformed MRE in diagnostic accuracy. Patients diagnosed with CD (N = 24) had higher SUV than patients not diagnosed with CD (N = 6) (3.34 vs. 1.84, p = 0.022). A diagnostic cut-off at SUV at 2.5 could be used (AUROC = 0.81). A higher SUV predicts need for immunosuppressive medication (p = 0.0026) and biologics (p = 0.0005). SUV correlates positively with Simple Endoscopic Score for Crohn's Disease (SES-CD), fecal calprotectin, and CRP and negatively with Hb and serum albumin.
conclusionIn future, [18F]-FDG PET-MRE can be used in diagnostics of small bowel CD as a safe alternative for capsule endoscopy. High SUV can predict a more progressive disease course and need for more advanced therapies.
introductionDiagnostics of small bowel Crohn's disease (CD) can be difficult. Combined positron emission tomography-magnetic resonance enterography (PET-MRE) can be used to evaluate intestinal metabolism, but clinical use has been limited due to accessibility, costs, absence of standardized methods, and diagnostic thresholds. Our aim was to show that combined PET-MRE can be used to diagnose active small bowel CD.
methodsWe performed a fusion PET-MRE scan with [18F]-FDG tracer to 30 patients with suspected small bowel CD in colonoscopy. Standardized uptake values (SUVs) were measured from small bowel. The diagnosis was confirmed with small bowel capsule endoscopy. Clinicians chose appropriate medication to each patient blinded from SUV results. Endoscopic, laboratory, and MRE findings were investigated in relation to SUV.
resultsFusion PET-MRE outperformed MRE in diagnostic accuracy. Patients diagnosed with CD (N = 24) had higher SUV than patients not diagnosed with CD (N = 6) (3.34 vs. 1.84, p = 0.022). A diagnostic cut-off at SUV at 2.5 could be used (AUROC = 0.81). A higher SUV predicts need for immunosuppressive medication (p = 0.0026) and biologics (p = 0.0005). SUV correlates positively with Simple Endoscopic Score for Crohn's Disease (SES-CD), fecal calprotectin, and CRP and negatively with Hb and serum albumin.
conclusionIn future, [18F]-FDG PET-MRE can be used in diagnostics of small bowel CD as a safe alternative for capsule endoscopy. High SUV can predict a more progressive disease course and need for more advanced therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.